AstraZeneca PLC Earnings - Q3 2026 Analysis & Highlights
AstraZeneca reported continued revenue and EPS growth, strong oncology and rare-disease performance, and progress across its pipeline, while discussing loss-of-exclusivity pressures, investment priorities, and its outlook for 2026 and beyond.
Key financial results
For the first nine months of 2026, total revenue grew 7% and product revenue grew 6%; alliance revenue rose 32%, driven by partnered medicines including Enhertu, Datroway, and Tezspire.
Core EPS increased 14% year over year in the first nine months.
Core gross margin was 83% year to date; management expected full-year core gross margin to be stable to slightly higher than in 2025.
Core R&D expense rose 5% year to date, representing 23% of revenue; core SG&A increased 4%, and total core operating expenses increased 5%.
Other operating income was $618 million for the first nine months, including $277 million in Q3 and $100 million from the sale of Zoryve royalties.
The core tax rate was 19% year to date.
Operating cash flow was $10.9 billion, below the comparative period, partly because the prior year included a Lynparza milestone and the company experienced working-capital effects associated with Farxiga’s U.S. loss of exclusivity.
Capital expenditure was $2.3 billion for the period.
Management did not provide a reported operating profit margin or a year-over-year gross-margin comparison in the call.
Business segment results
Oncology: First-nine-month revenue rose 16% to $21.9 billion, with Q3 growth of 17%; the United States grew 18% year over year in the first nine months, while Europe and emerging markets grew at mid-teens rates.
Key oncology Q3 results included Tagrisso revenue of $2.1 billion (+12%), combined Imfinzi and Imjudo revenue above $2 billion, Calquence revenue of $1.1 billion (+16%), Enhertu revenue of $969 million (+35%), Truqap revenue of $210 million (+9%), and Datroway revenue of $78 million.
BioPharmaceuticals: Q3 total revenue declined 6% to $5.6 billion; Respiratory & Immunology revenue grew 11% to $2.5 billion, while CVRM revenue declined 18% to $2.6 billion.
Respiratory & Immunology highlights included Tezspire at $429 million (+51%), Fasenra at $602 million (+14%), Breztri at $374 million (+14%), and Saphnelo at $235 million (+32%); Symbicort declined 11% to $660 million.
In CVRM, Farxiga declined 23% to $1.6 billion, reflecting U.S. loss of exclusivity and China volume-based procurement; Baxfendy recorded $9 million in Q3 revenue.
Rare Disease: First-nine-month revenue grew 11% to $7.5 billion, with double-digit growth across key medicines.
Rare Disease Q3 highlights included Ultomiris growth of 19% and Strensiq growth of 34%; Soliris revenue continued to decline amid conversion to Ultomiris and biosimilar pressure.
Capital allocation
Capital expenditure was $2.3 billion for the first nine months, and the company revised its full-year expectation to a low-teens percentage increase versus 2025.
Deal-related payments totaled $4.3 billion in the first nine months, including a $600 million upfront payment for the Dizal collaboration; milestone payments were around $2 billion, with approximately $2.5 billion expected for the full year.
AstraZeneca’s $2 billion Summit Therapeutics equity investment closed during October and was excluded from the deal-related payment figure; Q4 finance expenses were expected to include a one-time expense relating to the investment premium.
Gross debt and the current net debt-to-EBITDA ratio of 1.2 times were described as comfortable.
The three-year Reshaping for Sustainable Growth program is expected to incur up to $2 billion in one-time restructuring costs and deliver $1.5 billion in annualized pretax run-rate benefits, with activities expected to conclude by the end of 2029; the savings are intended to be reinvested in the company, particularly its pipeline.
The call did not specify plans for dividends, share repurchases, or debt repayments.
Industry trends and dynamics
Management described strong demand across therapy areas and geographies; oncology, rare disease, and R&I all delivered double-digit growth in the first nine months.
China’s reported growth continued to be affected by volume-based procurement (VBP); excluding this impact, China grew 13% in the first nine months.
Farxiga and Brilinta loss-of-exclusivity pressures weighed on CVRM, while Farxiga’s U.S. loss of exclusivity also affected working capital.
Management cited growing use of biologics in severe asthma and Tezspire’s launch in chronic rhinosinusitis with nasal polyps as drivers of R&I demand.
In oncology, management emphasized treatment moving into earlier disease settings and the use of combinations and ADCs to change treatment approaches.
Management described unmet need in COPD across a broad range of eosinophil levels, and said tozorakimab showed clinically meaningful exacerbation reductions across the studied groups.
Competitive landscape
Management said Tagrisso remains the backbone of care for EGFR-mutated lung cancer, with FLAURA2 maintaining a leading position in major markets; it highlighted combinations with Orpathys and Datroway as ways to extend Tagrisso-based treatment.
Calquence was described as the leading BTK inhibitor in first-line CLL across the top eight markets.
Enhertu’s U.S. growth was supported by demand in established breast cancer indications and contributions from first-line HER2-positive and early breast cancer settings.
In Symbicort, U.S. revenue declined 25% following the entry of a second generic competitor.
Management noted increasing competitive pressure from local Chinese companies, particularly in oncology, alongside potential benefits from collaboration and learning from those companies.
For puxi-sam, management cited broad B7-H4 expression in endometrial cancer and a stable linker associated with a lower rate of bone-marrow toxicity than some competing drugs as potential differentiators.
Management said AstraZeneca’s approach to metabolic disease aims to address interconnected conditions, including excess visceral fat, hypertension, cholesterol, pre-diabetes, diabetes, and kidney disease, rather than focusing only on weight reduction.
Macroeconomic environment
Management discussed MFN pricing considerations, noting that Europe and Japan are in the reference basket and that the framework uses GDP-adjusted U.S. prices; it characterized the intended direction as U.S. prices declining somewhat and European prices increasing somewhat over time.
Management described Japan’s efforts to make its innovation ecosystem more attractive and cited encouraging pricing, access, and reimbursement developments there; it also noted early signs of progress in some European countries.
In China, management cited policy emphasis on intellectual-property protection, regulatory data protection, and healthcare and innovation, while also acknowledging competitive pressure from domestic biopharma companies.
The call did not provide a specific outlook on inflation, recession, tariffs, or the broader business cycle.
Growth opportunities and strategies
AstraZeneca reported 12 positive Phase III program readouts since its full-year results and first approvals for four new medicines; management said the company had reached 14 approved new molecular entities toward its goal of 20 by 2030.
The positive Phase III readouts were said to represent more than $10 billion in non-risk-adjusted peak-year sales potential.
Management highlighted more than 20 planned key Phase III readouts in 2027, with non-risk-adjusted peak-year revenue potential of more than $20 billion and pivotal data expected for nine potential new medicines.
The company’s 2030 ambition is $80 billion in revenue; management said it believes pipeline opportunities can more than offset upcoming losses of exclusivity and support growth through the next decade.
Management identified 12 new molecular entity programs with peak revenue potential above $5 billion, including three already launched and three with positive Phase III data; it also cited four programs with potential peak-year revenue of $3 billion to $5 billion each.
The Summit collaboration will assess ivonescimab combinations with sone-ve and Datroway, with each company contributing its medicine and sharing trial costs.
In oncology, the company is advancing ADCs, immuno-oncology bispecifics, cell therapies, and T-cell engagers; it reported 15 Phase III trials for next-generation IO bispecifics across nine tumor types.
In weight management and cardiovascular risk factors, Phase III trials are underway for elecoglipron and have begun for the selective amylin receptor agonist lenbelintide.
The company expects to launch tozorakimab in the United States in Q1 2027, subject to regulatory approval.
Management said the restructuring program is intended to redeploy resources, align capabilities with future opportunities, and create capacity for investment without expanding the cost base as much; it cited technology and AI as contributors to productivity.
Financial Guidance and Outlook
AstraZeneca reiterated full-year 2026 guidance for total revenue growth in the mid-to-high single digits and core EPS growth in the low double digits.
Full-year core gross margin was expected to be stable to slightly higher than in 2025, while the core tax-rate expectation remained 18%–22%.
R&D expense was expected to be at the upper end of the low-20s percentage range of revenue for the full year.
Management expected a sequential Q4 step-up in operating expenses versus Q3 and said second-half gross margin would be below first-half levels, reflecting seasonal demand for lower-margin medicines; it also expected year-end effects from hospital budget capping and NRDL stock compensation in China.
Full-year capital expenditure was expected to increase by a low-teens percentage compared with 2025.
The company expected second-half other operating income to be slightly higher than first-half levels.
Management expected Q4 finance expenses to rise versus Q3 because of interest costs on bonds issued in Q3, lease expenses for the new Kendall Square R&D center, and the one-time Summit investment premium expense.
AstraZeneca did not give 2027 financial guidance on the call; management said it planned to provide guidance in February 2027.
Management expressed confidence in post-2030 growth based on its risk-adjusted pipeline forecasts, but said it had not decided whether or when to quantify a new post-2030 target.
